Autobio Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 500 million worth of its shares, under the authorization approved on February 20, 2024.
February 21, 2024
Share
Autobio Diagnostics Co., Ltd. (SHSE:603658) commences a share repurchases on February 21, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on February 20, 2024. As per the mandate, the company is authorized to repurchase up to CNY 500 million worth of shares. The shares will be repurchased at a price of CNY 60 per share. The source of funds for the repurchase program will be the company?s own funds. The shares repurchased will be canceled and the company?s registered capital will be reduced, which is conducive to safeguarding the company's value and shareholders' rights and enhancing investor confidence. The program will be valid for 12 months.
On May 29, 2024, the company announced that it adjusted the upper limit of the repurchase price of shares from CNY 60 per share to CNY 58.96 per share. The effective date for adjustment of the upper limit of the share repurchase price is June 5, 2024.
Autobio Diagnostics Co., Ltd. is a China-based company and mainly engaged in development, manufacture and sales of diagnostics products. The Company's main products include gnostic products, microbiology detection products, and related devices. The immunodiagnostic products include microplate chemiluminescence diagnostic reagents, Enzyme-Linked immunosorbent assay diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. The microbiology detection products include training detection reagents, susceptibility detection reagents and rapid detection reagents. The device products include microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers. The Company distributes its products in domestic markets.
Autobio Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 500 million worth of its shares, under the authorization approved on February 20, 2024.
AUTOBIO DIAGNOSTICS CO., LTD. 
